Literature DB >> 19544670

Inhibition of Nm23H2 gene product (NDPK-B) by angiostatin, polyphenols and nucleoside analogs.

Iain L O Buxton1.   

Abstract

Human breast cancer cells (MDA-MB-435s) secrete a nucleoside diphosphate kinase (NDPK-B) as a phosphoprotein capable of converting diphosphate nucleosides to triphosphate nucleotides for one round in the absence of a phosphoryl donor. Incubation of the partially purified NDPK-B (Nm23-H2 by Western blot) from [gamma32P]Pi-labeled cells with non-radioactive ADP results in the formation of [gamma32P]ATP (Proc. West. Pharmacol. Soc. 44: 61-63, 2001). The presence of a secreted protein that can maintain ATP levels in the vicinity of capillary and lymph vessels may support cancer metastasis in several ways based on the known actions of ATP at P2Y receptors: facilitate intravasation of breast cancer cells that migrate from a solid tumor, support their extravasation at a distal site, and stimulate angiogenesis. The putative role of angiostatin (AS) as an ATP-synthase inhibitor led us to test the notion that AS blocks NDPK-B activity. Addition of commercial AS (kringles 1-4) did not alter enzyme activity. However, AS produced by us and never lyophilized, blocked NDPK activity in a dose-dependent fashion consistent with the notion that extracellular ATP generation by tumor cells may be important to the development of metastases. The ability of 0.5 mg/ml angiostatin to block NDPK-B activity to approximately 75% of control activity compared poorly with the polyphenol inhibitors of. The catechin gallates, theaflavins and ellagic acid inhibited NDPK-B completely with the rank order of potency: EA > theaflavins > EGCG > ECG > PAPS. Our results suggest that the biological activity of angiostatin as a putative metastasis inhibitor may be in part the result of nm23 inhibition and that the production, lyophilization, packaging or storage of commercial angiostatin leads to the alteration of its biological activity against NDPK-B. Ellagic acid is a potent (IC50 = 10.5 microM) NDPK-B inhibitor that may prove useful in elucidating the role of cancer-cell secreted NDPK-B in tumor development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19544670      PMCID: PMC2702708     

Source DB:  PubMed          Journal:  Proc West Pharmacol Soc        ISSN: 0083-8969


  21 in total

1.  Secretion of a nucleoside diphosphate kinase (Nm23-H2) by cells from human breast, colon, pancreas and lung tumors.

Authors:  J Anzinger; N A Malmquist; J Gould; I L Buxton
Journal:  Proc West Pharmacol Soc       Date:  2001

2.  Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3'-digallate.

Authors:  Y C Liang; Y C Chen; Y L Lin; S Y Lin-Shiau; C T Ho; J K Lin
Journal:  Carcinogenesis       Date:  1999-04       Impact factor: 4.944

3.  Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture.

Authors:  H Miyazaki; M Fukuda; Y Ishijima; Y Takagi; T Iimura; A Negishi; R Hirayama; N Ishikawa; T Amagasa; N Kimura
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

4.  An Inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface.

Authors:  Nick R Burwick; Miriam L Wahl; Jun Fang; Zhaoxi Zhong; Tammy L Moser; Bo Li; Roderick A Capaldi; Daniel J Kenan; Salvatore V Pizzo
Journal:  J Biol Chem       Date:  2004-11-04       Impact factor: 5.157

5.  Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice.

Authors:  A Sckell; N Safabakhsh; M Dellian; R K Jain
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

6.  The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

Authors:  S Gately; P Twardowski; M S Stack; D L Cundiff; D Grella; F J Castellino; J Enghild; H C Kwaan; F Lee; R A Kramer; O Volpert; N Bouck; G A Soff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

Review 7.  Angiostatin and anti-angiogenic therapy in human disease.

Authors:  Miriam L Wahl; Tammy L Moser; Salvatore V Pizzo
Journal:  Recent Prog Horm Res       Date:  2004

8.  Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin.

Authors:  T L Moser; D J Kenan; T A Ashley; J A Roy; M D Goodman; U K Misra; D J Cheek; S V Pizzo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

9.  Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis.

Authors:  A Yamaguchi; T Urano; S Fushida; K Furukawa; G Nishimura; Y Yonemura; I Miyazaki; G Nakagawara; H Shiku
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

View more
  13 in total

Review 1.  Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis.

Authors:  Iain L O Buxton; Nucharee Yokdang; Robert M Matz
Journal:  Cancer Lett       Date:  2010-05-28       Impact factor: 8.679

2.  Progress on Nme (NDP kinase/Nm23/Awd) gene family-related functions derived from animal model systems: studies on development, cardiovascular disease, and cancer metastasis exemplified.

Authors:  Tien Hsu; Patricia S Steeg; Massimo Zollo; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-15       Impact factor: 3.000

Review 3.  Extracellular NME proteins: a player or a bystander?

Authors:  Patrizia Romani; Marilena Ignesti; Giuseppe Gargiulo; Tien Hsu; Valeria Cavaliere
Journal:  Lab Invest       Date:  2017-10-16       Impact factor: 5.662

4.  Measurement of human breast tumor cell-secreted shNDPK-B in a murine breast cancer model suggests its role in metastatic progression.

Authors:  Nucharee Yokdang; Noah D Buxton; Iain L O Buxton
Journal:  Proc West Pharmacol Soc       Date:  2009

5.  Ebselen is a potent non-competitive inhibitor of extracellular nucleoside diphosphokinase.

Authors:  Lucia Semianrio-Vidal; Catharina van Hesuden; Govindasamy Mugesh; Eduardo Rodolfo Lazarowski
Journal:  Purinergic Signal       Date:  2010-11-03       Impact factor: 3.765

6.  Blockade of extracellular NM23 or its endothelial target slows breast cancer growth and metastasis.

Authors:  Nucharee Yokdang; Senny Nordmeier; Katie Speirs; Heather R Burkin; Iain L O Buxton
Journal:  Integr Cancer Sci Ther       Date:  2015

7.  Ellagic acid and human cancers: a systems pharmacology and docking study to identify principal hub genes and main mechanisms of action.

Authors:  Hamid Cheshomi; Ahmad Reza Bahrami; Maryam M Matin
Journal:  Mol Divers       Date:  2020-05-14       Impact factor: 2.943

8.  Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters.

Authors:  Ying-Si Wu; Jar-Yi Ho; Cheng-Ping Yu; Chun-Jung Cho; Chia-Lun Wu; Cheng-Shuo Huang; Hong-Wei Gao; Dah-Shyong Yu
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

9.  Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies.

Authors:  Junko Okabe-Kado; Takashi Kasukabe; Yasuhiko Kaneko
Journal:  Adv Hematol       Date:  2011-09-19

10.  A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling.

Authors:  N Yokdang; J D Tellez; H Tian; J Norvell; S H Barsky; M Valencik; I L O Buxton
Journal:  Br J Cancer       Date:  2011-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.